PBYI
PUMA BIOTECHNOLOGY, INC.
NASDAQ · Healthcare · Biotechnology · US
$10.69
+4.60%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$10.47
From 52W high−5.06%
Volume475066.00
Market cap$551.82M
P/E (TTM)19.9x
P/S (TTM)2.4x
Div yield—
Key dataNov 4, 2026
Open
$10.47
From 52W high
−5.06%
Volume
475066.00
Market cap
$551.82M
ValuationView details →
P/E (Fwd)
46.5x
EV/EBITDA
10.2x
P/E (TTM)
19.9x
RSI (14)
57.1
MomentumView details →
1D Return
+4.60%
YTD Return
+80.17%
SummaryUpdated Jun 1, 2026
Puma Biotechnology, Inc. (NASDAQ:PBYI) is a Los Angeles-based biopharmaceutical company founded in 2010 that focuses on developing and commercializing innovative cancer treatments. The company went public in 2012 and has established itself as a specialized oncology company with a primary focus on HER2-positive breast cancer therapies. Puma's flagship product is NERLYNX (neratinib), an oral medication approved for treating early-stage and advanced HER2-positive breast cancer patients. The company has built a global presence through licensing partnerships and continues to expand its pipeline through clinical development programs and potential in-licensing opportunities.
Similar companies
Latest newsMore news →
PUMA BIOTECHNOLOGY, INC. announced that it will issue its third-quarter 2026 financial results after the market close on November 5, 2026.13d agoPuma Biotechnology initiated ALISCA-Lung2, a Phase II trial of alisertib in combination with paclitaxel for patients with advanced small cell lung cancer.48d ago